ICMJE DISCLOSURE FORM

Date: Oct 23, 2023
Your Name: Nobukazu Fujimoto
Manuscript Title: Subtypes of EGFR exon 19 deletion mutations
Manuscript number (if known): TLCR-23-680

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
Time frame: Since the initial planning of the work				
1	All support for the present			
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
	Time frame: past 36 months			
2	Grants or contracts from	ONO	Payments were made to my institution.	
	any entity (if not indicated	Bristol-Meyers Squib	Payments were made to my institution.	
	in item #1 above).	Glaxo SmithKline	Payments were made to my institution.	
3	Royalties or licenses	None		
4	Consulting fees	None		

5	Payment or honoraria for	ONO	Payments were made to me.
	lectures, presentations,	Chugai	Payments were made to me.
	speakers bureaus,	Behringer Ingelheim	Payments were made to me.
	manuscript writing or	AstraZeneca	Payments were made to me.
	educational events	NIHON KAYAKU	Payments were made to me.
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	-		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	' ' ' '	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		
	Illianciai illici ests		

Please summarize the above conflict of interest in the following box:

The author reports grants and personal fees from ONO, Bristol-Meyers Squib, and Glaxo SmithKline, and personal fees from ONO, Chugai, Behringer Ingelheim, NIHON KAYAKU, and AstraZeneca.

Please place an "X" next to the following statement to indicate your agreement:

X _ I certify that I have answered every question and have not altered the wording of any of the questions on this form.